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Aim of database: The Danish National Lymphoma Registry (LYFO) was established in order 
to monitor and improve the diagnostic evaluation and the quality of treatment of all lymphoma 
patients in Denmark.
Study population: The LYFO database was established in 1982 as a seminational database 
including all lymphoma patients referred to the departments of hematology. The database became 
nationwide on January 1, 2000.
Main variables: The main variables include both clinical and paraclinical variables as well as 
details of treatment and treatment evaluation. Up to four forms are completed for each patient: a 
primary registration form, a treatment form, a relapse form, and a follow-up form. Variables are 
used to calculate six result quality indicators (mortality 30 and 180 days after diagnosis, response 
to first-line treatment, and survival estimates 1, 3, and 5 years after the time of diagnosis), and 
three process quality indicators (time from diagnosis until the start of treatment, the presence 
of relevant diagnostic markers, and inclusion rate in clinical protocols).
Descriptive data: Approximately 23,000 patients were registered in the period 1982–2014 
with a median age of 65 years (range: 16–100 years) and a male/female ratio of 1.23:1. Patients 
can be registered with any of 42 different subtypes according to the World Health Organization 
classifications.
Conclusion: LYFO is a nationwide database for all lymphoma patients in Denmark and includes 
detailed information. This information is used for both epidemiological research and clinical 
follow-up as well as for administrative purposes.
Keywords: lymphoma, treatment, clinical database, quality assurance
Aim of database
Malignant lymphoma is a heterogeneous group of diseases with a wide spectrum of 
histological subtypes. Traditionally, malignant lymphomas have been divided into 
Hodgkin lymphomas and non-Hodgkin lymphomas. More than 40 subgroups are 
defined; both indolent and aggressive variants exist, and a wide range of treatment 
is used. The Danish National Lymphoma Registry (LYFO) was established in 1982, 
covering the western part of Denmark (Jutland and Funen), including patients with 
non-Hodgkin lymphoma. In 1998, Hodgkin lymphoma was also included, as the 
former term “Hodgkin Disease” was changed. As of January 1, 2000, the LYFO 
became nationwide.
The LYFO aims to register the clinical and paraclinical characteristics of patients 
diagnosed with malignant lymphoma in Denmark. The LYFO aims to monitor the 
clinical course of the disease as well as to monitor and improve the quality of treatment 
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nationwide by benchmarking departments and patient risk 
groups.
Study population
The LYFO includes all patients diagnosed with malignant lym-
phoma in Denmark, referred to one of the ten departments of 
hematology. Patients with cutaneous lymphomas, some HIV+-
associated lymphomas, and some lymphomas where treatment 
is futile are not referred to hematological departments and 
hence not registered in the LYFO. This represents ∼5% of 
the lymphoma patients in Denmark. Patients diagnosed and 
treated outside of Denmark are not registered; according to 
the database registration, it is two patients per year. Patients 
who relapse where the initial lymphoma diagnosis was prior 
to start of the registry in that region are not registered. By the 
end of 2014, ∼23,000 patients were registered since 1982.
Main variables
Since it is a national quality database, all departments of 
hematology are obligated to register patients in the LYFO 
at the time of diagnosis, at the end of first-line treatment, at 
relapse, and at the end of follow-up or death.
Standardized forms are used to collect data on lymphoma 
patients (Table 1). Since 2005, the registration is submitted 
electronically through a secure Internet-based database 
system, and all information is saved electronically. For each 
patient, four forms are available in a consecutive manner 
(Figure 1).
Primary registration form
At the time of diagnosis, a primary registration form is 
requested. The department responsible for the treatment ini-
tiation and evaluation has the obligation to enter the form. The 
diagnosis is coded according to the WHO Classification of 
Tumours of Haematopoietic and Lymphoid Tissues.1 Since 
a minor subset has a discordant diagnose, this is also regis-
tered. Ann Arbor stage, B-symptoms, largest tumor diameter, 
Eastern Cooperative Oncology Group performance status, 
concomitant neoplastic diseases, and treatment strategy are 
required in the form. In addition to a number of laboratory test 
results (Table 1), information of each nodal and extranodal 
involvement sites is required.
Treatment form
The treatment form consists of detailed information on the 
first-line treatment: chemotherapy regimens, treatment with 
monoclonal antibodies, radiotherapy, radioimmunotherapy, 
major surgery, and date and type of eventually autologous 
Table 1 Data recorded on four registration forms used by the 
Danish National Lymphoma Registry
Registration form and 
time of registration
Variables
Registration form Diagnosis according to wHO (2008)/iCD-10
At diagnosis Date of diagnosis
Discordant lymphoma
Ann Arbor stage
B-symptoms
Largest tumor diameter
ECOG performance status
Planned treatment
Participation in clinical research protocol
Nodal and extranodal sites involved
Laboratory values (hemoglobin, 
thrombocytes, leucocytes, lymphocytes, 
albumin, calcium, bilirubin, alanine 
transaminase, alkaline phosphatase, lactate 
dehydrogenase, beta-2 microglobulin, and 
immunoglobulins A, G, and M)
Primary treatment form Chemotherapy
At the end of first-line 
treatment
immunotherapy
Radioimmunotherapy
Radiotherapy
Major surgery
High-dose therapy with autologous stem-cell 
transplantation
Other treatment
Response evaluation
Toxicity CTC grades iii and iv
Relapse Date of relapse
At the time of relapse Histology (new biopsy)
CNS involvement at relapse
Treatment
Chemotherapy
immunotherapy
Radioimmunotherapy
Radiotherapy
Major surgery
High-dose therapy with autologous stem-cell 
transplant
Other treatment
Response evaluation
Follow-up/death vital status
Date of follow-up/date of death
Remission status
Termination of outpatient follow-up
Abbreviations: wHO, world Health Organization; iCD-10, international 
Classification of Diseases, tenth edition; ECOG, Eastern Cooperative Oncology 
Group; CTC, common toxicity criteria; CNS, Central nervous system.
stem-cell therapy. Dates for starting and ending of the 
treatment are requested. A response assessment is required 
and has been adjusted to the different versions of the Inter-
national Response Criteria for Malignant Lymphoma.2 
Furthermore, toxicity assessment is recorded for patients 
experiencing toxicity grades III and IV.3
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Relapse form
In the case of clinical or histologically confirmed relapse or 
refractory disease, defined as progression within 3 months 
after termination of first-line treatment, a relapse form is 
requested. This form is also completed for all patients who 
were initially observed without need of treatment.
The relapse form requires date of relapse, lymphoma 
histology at relapse, treatment information of second-line 
treatment, and response assessment identical to the treat-
ment form.
Follow-up form
A follow-up form is requested at death or termination of 
outpatient follow-up.
This form includes information on vital status, date of 
follow-up or death, and disease remission status.
The four schemes in the database are merged to an 
analyzable dataset, where new data fields are derived from 
the entered values in the schemes. This process utilizes 
calculation of a number of prognostic indexes such as the 
International Prognostic Index (IPI)4 and the Follicular 
Lymphoma International Prognostic Index5 and a number 
of nodal and extranodal sites, in addition to calculation of 
both result and process quality indicators. Result quality 
indicators are mortality 30 and 180 days after diagnosis for 
patients receiving treatment, response to first-line treatment 
and Kaplan-Meier survival estimates 1, 3, and 5 years after 
the time of diagnosis. The process quality indicators include 
time from diagnosis to start of treatment, fulfillment of 
entered data used in the International Prognostic Index, and 
the inclusion rate in clinical trials.
To ensure high registry completeness, the LYFO is cross-
referenced with the Danish National Patient Registry and the 
National Pathology Registry. Since all patients with a hospital 
admission, both as inpatient and outpatient, are registered in 
the Danish National Patient Registry with diagnosis and date 
of contact, all patients referred to a hematological depart-
ment are identified by this cross-reference.6 Departments can 
instantly retrieve lists of patients with missing registration in 
the database, both at time of diagnosis and time of an eventual 
relapse. All departments register in the LYFO and fulfill the 
demand of coverage of at least 90%.
Follow-up
In addition to the follow-up form, which is completed at the 
time of termination of outpatient follow-up or death, which-
ever occurs first, a linkage to the Danish Civil Registration 
System secures that date of death is available.7 Thereby, no 
patient is lost to follow-up.
Examples of research
Data from the LYFO has for decades been used for both clini-
cal epidemiological research and for monitoring the treatment 
of lymphoma patients in Denmark.8 The Danish Lymphoma 
Group, who runs the database, publishes annually a report 
based on data from the LYFO in collaboration with Registry 
Support Center of Epidemiology and Biostatistics (East).9 
The quality indicators are presented for each department by 
year together with comments from clinicians and epidemiolo-
gists. The reports have shown improved 180 days mortality 
for patients with diffuse large B-cell lymphoma (DLBCL), 
improving from 12% to 10% during the past 4 years. The 
annual report is publically available and is used by both clini-
cians and for administrative purposes. In case of one depart-
ment having significant worse outcome than the others, the 
administrative staff will examine the numbers and differences 
and draw the clinicians’ attention to the differences in order 
to standardize treatment and outcome. As an example, the 
survival for patients with DLBCL was significantly lower in 
two out of ten departments in 2001–2007. The survival has 
increased, but is now at the same level for all departments 
due to publication of the survival results (Figure 2).
A substantial number of papers originated from the 
LYFO have been published in the past decade in inter-
national journals, and collaboration with other national 
databases has resulted in unique publications.9–13 In 2014, 
a publication of mantle cell lymphoma showed male sex 
to be an independent negative prognostic factor, and that 
Primary
registration form
n=23,071
Treatment form
n=20,216
Relapse
 form
n=5,693
Follow-up form
n=11,588
Figure 1 The four registration forms and the number registered in the LYFO for each form.
Notes: All patients have a primary registration form, whereas only patients receiving treatment have a treatment form, only patients who relapse have a relapse form, and 
only patients where outpatient follow-up is terminated have a follow-up form.
Abbreviation: LYFO, Danish National Lymphoma Registry.
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both Rituximab and autologous stem-cell transplant were 
independently associated with better outcome.11 A study on 
routine imaging in the follow-up setting after treatment for 
DLBCL compared the widespread use of routine imaging 
in Denmark with the more restrictive use in Sweden. No 
impact was found on survival, and the study concludes that 
routine imaging for DLBCL in the first complete remission 
is not recommended.13
Data quality in the LYFO has recently been measured 
through a validation process, and the data quality and 
coverage was found to be very high with positive predic-
tive values for individual variables ranging from 87% to 
100% using individual medical records as reference and a 
registration completeness of 94.9% using Danish National 
Patient Registry (DNPR) as reference.14,15
Administrative issues and funding
All Danish departments of hematology are responsible for 
reporting to the database. Health care professionals (eg, 
medical doctors, study nurses) report to the database, and 
consent is not required from patients due to the Danish 
legislation. Registration in the LYFO is approved by the 
National Board of Health and the Danish Data Protection 
Agency (2006-54-2093).
A data entry manual is publically available, and training is 
performed locally. Prior to submission of a form, an internal 
validation of the data fields is performed and the clinician 
has to clarify open issues (eg, date of diagnosis, lymphoma 
subtype) before submission of the form can be performed. 
Furthermore, a warning sign appears if an abnormal value 
has been entered.
Funding from the Danish Regions allows the maintenance 
and development of the database and the database office. 
Registry Support Center of Epidemiology and Biostatistics 
East is responsible for IT support as well as statistical and 
epidemiological support.
Conclusion
The LYFO is a nationwide registry, established in 1982, with 
extensive information on all lymphoma patients treated at a 
department of hematology in Denmark. The database is used 
for quality assurance, clinical epidemiological research, and 
administrative purposes.
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